1. Within your health trust, how many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents?
a. Carboplatin (monotherapy or in combination with 5-FU)
b. Cisplatin (monotherapy or in combination with 5-FU)
c. Cetuximab with/without chemotherapy
d. Cetuximab with radiotherapy
e. Pembrolizumab monotherapy
f. Pembrolizumab with chemotherapy
g. Nivolumab
h. Docetaxel (monotherapy or in combination with 5-FU)
i. Fluorouracil (5FU)
j. Radiotherapy only
k. Other
2. For the patients treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the therapies listed in the first question, please provide:
a. Total number of head and neck cancer patients
b. Number of locally advanced head and neck cancer patients
c. Number of recurrent and/or metastatic head and neck cancer patients
3. Within your health trust, how many patients have been treated in the past 3 months with the following agents for colorectal cancer [CRC]?
a. Aflibercept
b. Bevacizumab
c. Capecitabine
d. CAPIRI
e. CAPOX (XELOX)
f. Cetuximab in combination with FOLFIRI
g. Cetuximab in combination with FOLFOX
h. Cetuximab not in combination with FOLFIRI or FOLFOX
i. Irinotecan only
j. FOLFIRI
k. FOLFOX
l. Fluorouracil (5FU) only
m. Oxaliplatin only
n. Panitumumab in combination with FOLFIRI
o. Panitumumab in combination with FOLFOX
p. Panitumumab not in combination with FOLFIRI or FOLFOX
q. Pembrolizumab
r. Nivolumab
s. Raltitrexed
t. Ramucirumab
u. Regorafenib
v. Sorafenib
w. Other SACT